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Abstract
Nitroxides occupy a privileged position among plausible metal-free magnetic resonance imaging 
(MRI) contrast agents (CAs) due to their inherently low-toxicity profiles; nevertheless, their 
translational development has been hindered by a lack of appropriate contrast sensitivity. 
Nanostructured materials with high nitroxide densities, where each individual nitroxide within a 
macromolecular construct contributes to the image contrast, could address this limitation, but the 
synthesis of such materials remains challenging. Here, we report a modular and scalable synthetic 
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approach to nitroxide-based brush-arm star polymer (BASP) organic radical CAs (ORCAs) with 
high nitroxide loadings. The optimized ∼30 nm diameter “BASP-ORCA3” displays outstanding 
T2 sensitivity with a very high molecular transverse relaxivity (r2 > 1000 mM−1 s−1). BASP-
ORCA3 further exhibits excellent stability in vivo, no acute toxicity, and highly desirable 
pharmacokinetic and biodistribution profiles for longitudinal detection of tumors by MRI. When 
injected intravenously into mice bearing subcutaneous plasmacytomas, BASP-ORCA3 affords 
distinct in vivo visualization of tumors on translationally relevant time scales. Leveraging its high 
sensitivity, BASP-ORCA3 enables efficient mapping of tumor necrosis, which is an important 
biomarker to predict therapeutic outcomes. Moreover, BASP-ORCA3 allows for detection of 
millimetric tumor implants in a disseminated murine model of advanced-stage human ovarian 
cancer that possess genetic, histological, and vascular characteristics that are similar to those seen 
in patients. This work establishes BASP-ORCA3 as a promising metal-free spin contrast agent for 
MRI.
Graphical Abstract
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Imaging technologies have revolutionized clinical practice as well as drug discovery and 
development efforts.1–4 For many imaging modalities, contrast agents (CAs) are used to 
improve signal-to-noise ratios (SNRs) for the detection of pathologic disease states.5–7 For 
example, 18F ﬂuorodeoxyglucose (18F-FDG), iodine, as well as gadolinium chelates and iron 
oxide nanoparticles are among the most commonly utilized CAs for positron emission 
tomography (PET), computed tomography (CT), and magnetic resonance imaging (MRI), 
respectively.8–10 Among these imaging modalities, MRI enables noninvasive monitoring of 
disease progression at more frequent time intervals and minimizes patient exposure to 
ionizing radiation, which are key advantages.11–15 MRI often suffers, however, from poor 
sensitivity, thus making CAs particularly useful in this context. The current generation of 
MRI CAs alter the relaxation time of surrounding water molecules in regions of interest 
(ROIs) via reduction of either the longitudinal relaxation time (T1 contrast) or the transverse 
relaxation time (T2 contrast).16–18 Note that some clinically utilized T2-based MRI CAs are 
metal-based nanoparticle formulations (e.g., superparamagnetic iron oxide nanoparticles 
(SPIONs)). While metal-based CAs have been shown to be generally nontoxic over short 
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time scales, chronic toxicity concerns remain for patients that require repeated or prolonged 
CA exposure.19–21 For example, studies as early as 2007 have demonstrated that gadolinium 
(Gd) chelates may be associated with nephrogenic systemic fibrosis (NSF); thus, their use 
has been prohibited in patients with renal insuﬃciency.22,23 Iron-based nanoparticle CAs 
(e.g., SPIONs), on the other hand, have also encountered safety concerns, leading to 
discontinuation of their development or withdrawal from the market.19,24,25 The only 
remaining United States Food and Drug Administration (FDA)-approved and available 
SPION is ferumoxytol, which continues to be used off-label as an MRI CA though it has its 
own safety concerns.19,24–27 Note that diagnostic CAs are held to a very high safety 
standard as they are often administered to healthy patients for disease screening.18 To date, 
the major design principle employed to overcome the toxicities of metal-based CAs has been 
to shorten their in vivo circulation times in order to minimize accumulation in otherwise 
healthy organs.28–30 While several metal-based CAs have been developed that have met 
these objectives, they are inherently not suitable for imaging over long time scales (e.g., 
several hours to days) as they are designed to clear rapidly from the body. The development 
of safer nanoparticle-based CAs that feature longer circulation times could enhance the 
signal-to-noise ratio (SNR) of MRI and allow for a higher uptake in tumor tissue and 
internalization by tumor cells, which could lead to applications such as monitoring of drug 
release.
It has been hypothesized that organic-based MRI CAs will be inherently safer than those 
based on metals and that they may provide opportunities for functional or responsive MR 
imaging (e.g., via codelivery of drug molecules or through leveraging the reactivity of 
organic molecules).31–34 This potential has driven several distinct approaches in the 
development of metal-free CAs. For example, 19F,35,36 hyperpolarized 13C,37,38 and 
chemical exchange saturation transfer (CEST)39,40 CAs have all shown promise for MRI; 
the use of these agents, however, often requires specific equipment and personnel with 
specialized training that do not currently exist in clinical settings. Alternatively, 
paramagnetic nitroxides represent a promising class of organic radical contrast agents 
(ORCAs)31,32 that are nontoxic and function via principles that are identical to those of 
current metal-based CAs. As such, an appropriately sensitive ORCA could potentially be 
integrated into existing clinical protocols to achieve safe long-term MRI contrast. 
Historically, the development of nitroxide-based ORCAs for MRI applications33,34 has been 
limited due to two critical weaknesses: (1) their low relaxivity (due to 1 unpaired electron 
per nitroxide as compared to 7 per Gd(III) or 5 per Mn(II) ion); and (2) their rapid in vivo 
reduction to diamagnetic hydroxylamines, which are MRI-inactive.41 Notably, the reducing 
properties of nitroxides have been exploited for several redox-based imaging applications on 
short time scales.42–44 In addition, progress toward the development of significantly more 
stable “reduction resistant” ORCAs has been made.45–48 Moreover, several groups have 
developed nitroxide-based MRI CAs49 where nitroxides are incorporated into a multitude of 
scaffolds ranging from cyclodextrin50 and lipids51 to polymeric systems,52–54 including 
polyurethane55 or polyacetylene.56 Despite such advances, these systems generally suffer 
from low water solubility, poor nitroxide reduction resistance, insuﬃcient relaxivity, and/or 
a lack of in vivo optimization that precludes further development. Further clinical translation 
of ORCAs requires materials with improved circulatory half-lives, pharmacokinetic/
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biodistribution profiles, stability, and MRI sensitivity. For example, to our knowledge, there 
are no examples of tumor detection using nitroxide-based CAs for MRI in translationally 
relevant in vivo models and over extended time scales.
Over the past several years, our group has developed brush-arm star polymers (BASPs) for 
applications that include combination drug delivery and molecular imaging.48,57–61 BASPs 
are prepared via “brush-first” ring-opening metathesis polymerization (ROMP),57 which is a 
convergent and highly scalable process.61 BASPs carry a payload (e.g., drug or imaging 
agent) at the interface between a cross-linked core and a protective hydrophilic polyethylene 
glycol (PEG) shell. The payload is covalently attached to the BASP building blocks, which 
are branched macromonomers (MMs); BASPs with multiplexed functionality can be 
prepared in a simple “plug-and-play” fashion via mixing of different MMs at predetermined 
ratios.48,58–61 In addition, the cross-linked core can be engineered to be stimuli-responsive, 
enabling controlled release of therapeutic or imaging agents while leaving biodegradable 
and/or low mass byproducts.48,58–61 BASPs exhibit consistent in vivo properties, including 
pharmacokinetic and biodistribution profiles, that are independent of their payload.48,60,61 
Moreover, their shells consist of PEGylated bottlebrush polymers, resulting in an extremely 
dense, hyperbranched nanoarchitecture that maintains a relatively small size (∼30 nm) that 
enables accumulation in poorly permeable solid tumors.18,62,63 Finally, we emphasize that 
the major component of our BASPs is PEG, which is a commonly used biomaterial with 
acceptable safety characteristics over long time scales.18,24,61 BASP excretion profiles have 
been extensively examined in murine models, using ﬂuorescence microscopy in conjunction 
with histopathological analyses, demonstrating elimination over several months.61
Despite the advances described above, all of our reported BASPs to date have been made by 
a synthetic approach that results in a single functional species per MM, which has limited 
the overall payload to ∼5–10% by mass. In the context of MR imaging, while our previously 
reported BASP-ORCA1, which carries the reduction resistant cyclohexyl nitroxide (“chex”), 
displays high relaxivity and stability for a nitroxide-based ORCA, its low chex loading 
(6.4% w/w of conjugated species chex-N3; see the Supporting Information (SI) for details) 
limits its imaging utility. While MRI of a simple subcutaneous tumor has been realized with 
this construct, such murine tumor models are inherently easy to visualize using nanomaterial 
constructs due to their exaggerated vascularity.48 To translate a BASP-based ORCA to the 
clinic, a much higher chex loading is required in order to achieve a suitable molecular 
relaxivity at a lower dose, which in turn would require a complete redesign of the BASP 
synthetic approach. Such a redesign may enable the demonstration of effective contrast in 
orthotopic tumor models that better recapitulate human disease.
Here, we present an approach to BASP synthesis that enables a second generation of BASP-
based ORCAs that overcome the above challenges. The strategy transforms a previously 
four-step linear synthesis, requiring four chromatography steps (43% overall yield on the 
∼0.1 g scale), to an overall three-step convergent synthesis (two-step longest linear 
sequence) that requires no chromatography and that provides our desired BASP precursor in 
92% overall yield on the 100 g scale.64 Most relevant to this work is the fact that this 
redesigned approach enables the iterative addition of payload to provide for conjugation of 
multiple chex groups per MM. These major breakthroughs in terms of scalability and 
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payload enhancement are deployed herein to prepare BASPs with three chex groups per 
repeat unit (BASP-ORCA3), which have a greatly increased mass fraction of chex 
(theoretical loading of conjugated species chex-N3 in BASP-ORCA3 = 16.7% w/w). Due to 
this enhanced chex density and the retained relaxivity enhancement imparted by the BASP 
scaffold, BASP-ORCA3 features a very high r2 transverse relaxivity of >1000 mM−1 s−1 per 
BASP molecule, which is more than double that of the previous “gold standard” (BASP-
ORCA1) for T2 ORCAs.48 Leveraging the modular nature of BASP synthesis, a secondary 
probe consisting of a near-infrared ﬂuorophore (NIRF) may also be incorporated into BASP-
ORCA3 to enable in vivo longitudinal detection of tumors via dual MR/optical imaging. The 
stability and safety of BASP-ORCA3 were examined, and its pharmacokinetic and 
biodistribution profiles were explored. BASP-ORCA3 generated stable T2 contrast over a 
time scale that is relevant for translational applications (i.e., ≥24 h postinjection), which 
enabled highly sensitive in vivo MRI of tumors in two distinct murine models of human 
cancer (subcutaneous plasmacytomas and disseminated ovarian tumor implants). In addition 
to achieving selective visualization of large subcutaneous tumors as well as small (<5 mm) 
tumors in the disseminated model, BASP-ORCA3 allowed for detailed mapping of tumor 
architectural features with potential prognostic significance (e.g., the presence of tumor 
necrosis that correlates with therapeutic outcomes and tumor activity).
RESULTS AND DISCUSSION
To maximize the relaxivity of BASP-ORCAs, we sought to increase chex loading without 
otherwise altering the physical properties or the optimized sizes of the resultant constructs. 
To achieve this goal, MMs with one, two, or three alkyne functional handles were prepared;
64
 reduction-resistant chex-N3 molecules were then appended to these MMs via copper-
catalyzed azide–alkyne cycloaddition to provide mono-, bis-, and tris-chex MMs (chexx-
MM, x = 1, 2, 3). Matrix-assisted laser desorption ionization time-of-ﬂight (MALDI-TOF) 
mass spectra (Figures S1–S3) and double integration (spin counting) of the electron 
paramagnetic resonance (EPR) spectra of chexx-MM, x = 1–3 (Figure S4) supported the 
presence of one, two, and three nitroxides, respectively. Notably, the theoretical mass 
fraction of chex-N3 increases significantly with x: from 9.4% w/w (x = 1) to 22.6% (x = 3) 
w/w, which is the key to realizing high molecular relaxivity of BASPs in this work (vide 
infra).
BASP-ORCAs were synthesized from the corresponding chexx-MMs, using brush-first 
ROMP (Figure 1).48,57–60 For BASP candidates that were intended to be used for in vivo 
studies, a NIRF-conjugated MM (Cy-MM; 1 mol %) was also incorporated to enable in vivo 
tracking of the resulting BASP-ORCAs by both MRI (high resolution) and in vivo optical 
imaging (high sensitivity).48 Due to the ratiometric control that is provided by the 
convergent brush-first ROMP method, this dual imaging capability was readily achieved 
despite large differences in the concentration requirements for effective tissue enhancement 
that are inherent to the 2 different types of CAs (i.e., mM to μM for MRI and nM to pM for 
NIRF imaging).65 BASP-ORCAs with brush lengths (m) of 7–10 and cross-linker 
equivalences (N) of 20–30 were examined for doubly and triply loaded chexx-MMs (x = 2–
3) (Table S1); these conditions have previously been shown to yield BASPs of optimal size 
and aqueous solubility for in vivo applications.48,57–60 Gel permeation chromatography 
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(GPC) traces acquired from reaction mixtures revealed good MM-to-brush and brush-to-
BASP conversion in all cases (≥90% and ≥80%, respectively, Table S1, Figure S5). 
Moreover, for these m and N values, BASP-ORCAs with diameters of 25–51 nm (as 
determined by dynamic light scattering (DLS) and transmission electron microscopy 
(TEM)) were obtained (Table S1, Figure 2A,B). Based on a combination of size 
(hydrodynamic diameter = 29 ± 10 nm) and relaxivity considerations (vide infra), we chose 
the BASP-ORCA with x = 3, m = 7, and N = 20 (hereafter referred to as BASP-ORCA3) for 
further development. The progression from single- to double and triple-loading of chex in 
this system was included to demonstrate the well-behaved and modular characteristics of our 
platform. In the context of a translational applications, we decided to focus on BASP-
ORCA3 due to its highest nitroxide density and associated molecular relaxivity.
We compared the EPR spectra of chexx-MM (x = 1, 2, 3) to that of the resultant BASP-
ORCA to gain a better understanding of how increasing chex density in our materials 
impacts the nitroxide environment. Computational fitting of the EPR spectra for chexx-MM 
showed that increasing x led to longer correlation times for rotational diffusion and 
increased internitroxide interactions, which reﬂects the increased molecular size and chex 
density of these MMs (Figure S4). Compared to its constituent MM (chex3-MM), the EPR 
spectrum of BASP-ORCA3 was extensively broadened; three well-resolved peaks for chex3-
MM merged into one broad peak for BASP-ORCA3 (Figure 2C). Longitudinal (r1) and 
transverse (r2) relaxivities of BASP-ORCAs as a function of m, N, and x were measured and 
compared; the per chex values for both r1 and r2 were not altered upon single-, double-, or 
triple-loading (x = 1, 2, or 3 respectively) of chex groups (Table S1).47,48 Most importantly, 
the large enhancement in r2 upon incorporation of chex observed previously for BASP-
ORCA1 was retained;48 BASP-ORCA3 exhibited a per chex r2 value of 4.62 mM−1s−1, 
which is similar to BASP-ORCA1 (4.67 mM−1 s−1)48 and a ∼ 27-fold enhancement 
compared to the value obtained for the benchmark nitroxide 3-CP (Table S1). In addition, 
BASP-ORCA3 features a high chex loading (16.7% w/w; 0.474 mmol chex/g theoretical and 
0.473 mmol/g measured; 99.7% spin concentration as measured by EPR spectroscopy), 
good water solubility (>100 mg/mL), and an optimal size range (29 ± 10 nm by DLS, 43 ± 8 
nm by TEM) for prolonged in vivo circulation and passive tumor accumulation and 
penetration.66,67
As estimated from the molar mass obtained by GPC with static light scattering, BASP-
ORCA3 (Mw = 6.6 × 105 Da, Đ = 1.34) contains >200 chex groups, resulting in a molecular 
r2 value of >1000 mM−1 s−1 at 7 T. Compared to BASP-ORCA1 (molecular r2 ∼ 450 mM−1 
s−1 at 7 T),48 this exceptionally high relaxivity suggested that BASP-ORCA3 would display 
significantly greater MRI contrast at the same concentration. To test this hypothesis, we 
compared the performance of BASP-ORCA3 and BASP-ORCA1 as T2 contrast agents, 
using MRI phantoms. Indeed, BASP-ORCA3 displayed greater contrast than BASP-ORCA1 
at all examined equivalent w/v concentrations (Figures 3A and S6). We further compared 
their imaging sensitivity via incubation of BASP-ORCA3 and BASP-ORCA1 with clusters 
of MM.1S cells, which are derived from an established multiple myeloma cell line, in order 
to determine the minimal cluster size that is detectable by MRI (Figure 3B). Note that this 
detection parameter is a more relevant criterion for the intended use of CAs for in vivo 
tumor identification by MRI. A cluster of 500 MM.1S cells incubated with BASP-ORCA3 
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resulted in a ∼9.7% amplification in contrast enhancement, which increased linearly to 
∼24.8% for 50,000 cells; BASP-ORCA1, on the other hand, exhibited <10% enhancement at 
all examined conditions (Figure 3B).
To test whether the redesigned BASP nanostructure could still effectively shield the 
increased payload of chex from reduction by common biological reducing agents, BASP-
ORCA3 was exposed to excess ascorbate (Asc) and glutathione (GSH).41,68 We compared 
the reduction kinetics as measured by EPR spectroscopy of BASP-ORCA1 and BASP-
ORCA3 at constant equivalency of reducing agents per chex molecule; in other words, 
BASP-ORCA3 was exposed to a 3-fold higher concentration of reducing agents. Despite this 
difference, the extent of chex reduction remained the same between BASP-ORCA1 and 
BASP-ORCA3 (Figures S7 and S8, Table S2), suggesting that the installation of 3-fold more 
chex onto BASP-ORCA3 did not compromise chex stability. Note that BASP-ORCA1 has 
been demonstrated to provide suﬃcient nitroxide stability in vivo;48 hence, it was used in 
the current study as the benchmark for stability evaluation. The reduction process was also 
monitored by NIRF spectroscopy (Figures S9 and S10) to determine if the larger chex 
density of BASP-ORCA3 led to increased ﬂuorescence quenching.69 An increase of ∼60% 
ﬂuorescence intensity was observed upon chex reduction, suggesting minimal ﬂuorescence 
quenching compared to our previously reported bottlebrush polymer (Figure S10).47 Given 
the increased nitroxide payload of BASP-ORCA3, this finding is consistent with the ∼30% 
increase in ﬂuorescence intensity that has been observed in BASP-ORCA1 with similar 
kinetics.48 Taken together, these data strongly suggest that the incorporation of 3-fold 
greater nitroxide density in BASP-ORCA3 provides a large increase in molecular relaxivity 
without compromising the beneficial features of the BASP design (e.g., size control, 
stability, limited ﬂuorescing quenching) that are critical to its in vivo performance.
Having established the basic contrast enhancement and physical properties of BASP-
ORCA3, we further evaluated its performance in biological systems. In vitro cytotoxicity 
experiments were conducted by incubating BASP-ORCA3 at varying concentrations with 
different established cell lines: MM.1S, OVCAR8 (high-grade serous ovarian cancer), and 
HUVEC (human umbilical vein endothelial cells). Note that MM.1S and OVCAR8 cells 
were also employed to generate our in vivo model systems (vide infra); HUVEC cells were 
selected as a highly toxin-sensitive in vitro model system and to examine potential in vivo 
vascular toxicities that could be imparted by BASP-ORCA3. After 72 h of continuous in 
vitro exposure, which mimicked expected in vivo behavior during intravascular circulation 
and tumor extravasation,48,60 cell viability was determined by the CellTiter-Glo assay. The 
half-maximal inhibitory concentration (IC50) values of BASP-ORCA3 to affect the viability 
of MM.1S, OVCAR8, and HUVECs were 3.17, 3.81, and 8.12 mg/mL, respectively (Figure 
S11), suggesting negligible in vitro toxicity at practical concentrations. To evaluate the in 
vivo safety profile of BASP-ORCA3, we administered the agent via either intravenous (iv) 
or intraperitoneal (ip) injection to healthy balb/c mice at a fixed dose of 30 mg (1.5 g/kg, n = 
3 mice); the mice were euthanized 24 h later and their organs were excised for histological 
analyses after hematoxylin and eosin (H&E) staining. No signs of gross architectural 
distortion were observed in any major organ, including the lungs, liver, spleen, heart, and 
kidneys (Figure S12). These results were consistent with the well-known tolerability of 
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PEG18,66 and nitroxide-based31–34 materials, supporting the further examination of other in 
vivo performance characteristics of BASP-ORCA3.
The pharmacokinetic (PK) and biodistribution (BD) profiles of our BASP-ORCAs were 
evaluated by NIRF-based optical imaging, using an IVIS Imaging System with gating on the 
ﬂuorescence of ROIs in the Cy5.5 channel (λex/λem = 640/700 nm). Balb/c mice were 
administered BASP-ORCA3 by either iv (n = 3 mice) or ip injection (n = 3 mice) (Figures 
S13 and S14). For determination of PK parameters, blood samples were collected at 
predetermined time points for up to 72 h after administration. The blood samples were 
imaged ex vivo, using the IVIS instrument and the same imaging parameters as described 
above. The percent injected dose (%ID) was plotted as a function of time and fitted to a 
standard two-compartment model70 (Figures S13 and S14), yielding a blood-compartment 
half-life of 13 h (after ip administration) and 26 h (upon iv injection). BASP-ORCA3 
exhibited PK behavior consistent with other hyper-branched PEG-based nanomaterials.48,71 
It was cleared mainly through the liver with a minor contribution from the kidneys, allowing 
for the potential use of this nonmetal-based ORCA in patients with compromised renal 
function.
Having demonstrated the high tolerability and favorable in vivo PK/BD of BASP-ORCA3, 
its contrast sensitivity for in vivo T2-enhanced MRI of tumors was examined. BASP-
ORCA3 was evaluated in the context of a subcutaneous xenograft model of multiple 
myeloma, which is an incurable plasma cell dyscrasia that can lead to lytic bone lesions, 
defective hematopoiesis, and renal failure.72 SCID mice were injected with 2.0 × 106 MM.
1S cells in the ﬂank, establishing a plasmacytoma (i.e., a clinically observed extramedullary 
tumor that consists of multiple myeloma cells); the tumor of each mouse was allowed to 
grow to >1 cm in diameter. Randomized groups of tumor-bearing mice (n = 4) were then 
administered either BASP-ORCA3 or BASP-ORCA1 by iv injection and were imaged by 
MRI and NIRF-based optical imaging after 24 h. Qualitatively, mice in the two treatment 
groups displayed similarly eﬃcient accumulation of CAs at tumor sites as well as similar 
BD profiles (Figures 4A and S15). Quantitative analysis of T2 MR images of tumors 
revealed 12.4 ± 0.4% and 24.3 ± 0.7% (p < 0.05) contrast enhancement for mice injected 
with BASP-ORCA1 and BASP-ORCA3, respectively (Figure 4B,C).
We observed that necrotic tumor regions experienced greater contrast enhancement (Figure 
4B). These contrast changes reached 28.2 ± 2.7% for BASP-ORCA1 and 69.1 ± 3.6% for 
BASP-ORCA3 (p < 0.05) (Figure 4C). In order to evaluate the basis for the difference in 
intratumoral contrast enhancement, the treated tumors were excised; analyses were 
performed on parallel sections by light microscopy after H&E staining to evaluate tissue 
histology; and, ﬂuorescence microscopy was conducted to visualize the locations of the 
NIRF-containing CAs, revealing the specific accumulation of BASP-ORCAs in necrotic 
tumor regions (Figure 4D). While both BASP-ORCAs exhibited this behavior quantitatively 
(Figure 4C), this information went previously unnoticed due to the relatively lower relaxivity 
of BASP-ORCA1 (Figure 4B). Upon examination of the data in total, BASP-ORCA3 
outperformed BASP-ORCA1 with respect to its contrast enhancement capabilities and 
clearly deciphered the presence of necrotic tumor regions. With respect to the latter 
phenomenon, tumor necrosis commonly occurs in large subcutaneous tumors and especially 
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tumors composed of MM.1S cells.73 The presence of necrotic sites induces enhanced 
vascular permeability but limits parenchymal tumor diffusion,66 which, in turn, causes 
BASP-ORCAs to passively accumulate in perivascular spaces to a greater degree. This 
finding strongly advocates for the use of BASP-ORCA3 as an effective diagnostic tool for 
the detection of tumor necrosis, which is an important prognostic biomarker that is 
connected to various pathological states as well as to treatment outcomes, including the 
eﬃcacy of radiation and cytotoxic drug therapy.74
As it was important to confirm that the observed enhancements in MRI contrast were due to 
a higher chex density rather than to any improvements in tumor accumulation for BASP-
ORCA3 as compared to BASP-ORCA1, major organs from the same mice were harvested at 
the time of animal sacrifice (after imaging), homogenized, and characterized by EPR 
spectroscopy (to quantify chex radical concentration), by IVIS (to quantify NIRF content), 
and by the bicinchoninic acid assay (BCA assay; to measure the protein concentration in 
tissue samples). While the BD profiles of the two different BASP-ORCAs were similar as 
observed by NIRF-based imaging, EPR quantification revealed higher concentrations of 
chex in the various organs of animals injected with BASP-ORCA3, which is consistent with 
a higher density of chex on a per BASP basis (Figure S16). The chex concentration in the 
tumor was 0.68 ± 0.18 μmol chex/g protein for BASP-ORCA3, which is significantly higher 
than the 0.17 ± 0.04 μmol chex/g protein measured from the tumors of animals that had been 
administered BASP-ORCA1 (p < 0.05, 3.0–4.8% ID/g protein); these values are in good 
agreement with the differences in contrast enhancement that were observed in vivo, vide 
supra (Figures 4C and S16A).
To further evaluate BASP-ORCA3 as a tumor imaging platform, its threshold to detect 
minute tumor deposits was explored. For these studies, a murine model of advanced-stage 
and high grade serous ovarian cancer (HGSOC), consisting of intraperitoneal dissemination 
of OVCAR8 cells into nude mice, was employed; this model system exhibits a fast tumor 
growth rate, lower tumor vascularization, and the propensity to establish tumor implants on 
the serosal surfaces of peritoneal organs that range in size from 1 to 5 mm and that display 
similar metastatic patterns, genetic profiles, and histologic features to those of human 
HGSOCs.71,75 BASP-ORCAs were introduced into animals by ip injection, which is a 
clinically relevant mode of therapeutic administration in advanced-stage ovarian cancer that 
has been shown to promote marked accumulation of PEG-based nanomaterials in ovarian 
tumors for imaging and/or therapy.71,75,76 For this current study, NCR-NU mice (n = 5) 
were injected with OVCAR8 cells transfected with fireﬂy luciferase, allowing for facile 
monitoring of the in vivo dissemination and tumor growth via bioluminescence imaging 
(BLI) (Figure 5A). The tumor implants were allowed to establish for 22 days; mice were 
then randomized into groups with equivalent tumor burden. The animals were administered 
either BASP-ORCA3 or BASP-ORCA1 by ip injection. After 24 h, the mice were imaged 
by BLI, NIRF-based optical imaging, and MRI (Figures 5A–C and S17). Qualitatively, 
BASP-ORCAs (as monitored by NIRF-based optical imaging; Cy5.5) colocalized with 
OVCAR8 tumors (as visualized by BLI). Leveraging the high-resolution imaging 
capabilities of MRI, BASP-ORCAs were found to further enhance contrast sensitivity and 
enabled ready visualization of small tumor implants in T2-weighted MR images (Figure 
5C,D). Quantitative analysis revealed contrast enhancements of 14.3 ± 0.9% for BASP-
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ORCA1 and 33.6 ± 4.4% for BASP-ORCA3 (p < 0.05; Figure 5E), which corresponded to a 
2.3-fold improvement in sensitivity with BASP-ORCA3 as compared to its predecessor. 
Notably, this difference in contrast was consistent with the 2.6-fold increased payload of 
chex by weight for BASP-ORCA3.
Upon completion of the in vivo imaging studies, the organs of the mice were processed as 
previously described for the subcutaneous MM.1S model (vide supra) to confirm that the 
observed differences in contrast enhancement were again due to increased chex density 
(Figure 6). Indeed, the chex concentration in the organs of animals that were administered 
BASP-ORCA3 was generally higher than in those that were administered BASP-ORCA1 
(Figure 6B). In tumor tissue, a chex concentration of 2.63 ± 0.61 μmol chex/g protein was 
observed for animals in the BASP-ORCA3 group, whereas the tumors of mice that received 
BASP-ORCA1 possessed 1.00 ± 0.27 μmol chex/g protein (p < 0.05; Figure 6B). NIRF-
based optical imaging confirmed that these differences were due to the increased density of 
chex in BASP-ORCA3 when compared to BASP-ORCA1, as opposed to differences in the 
accumulation of these two particles in tumor tissues (Figure 6C). The observed tumor uptake 
was similar to that of other polymers that were introduced via the same injection route (ip) 
into this tumor model.71,76 We also note that, throughout both tumor imaging studies, the 
BD profiles of the BASP-ORCAs (Figures S15 and S17), which were determined by 
quantification of NIRF and EPR signals in ex vivo organ homogenates, were consistent with 
the BD/PK data acquired in the non-tumor-bearing balb/c mice (Figure S13 and S14), 
supporting the generalizability of our findings for immunocompetent subjects.
CONCLUSIONS
We report a new family of nanoparticles with an exceptionally high nitroxide density. Brush-
first ROMP of a triply loaded chex MM (chex3-MM) produced a macromolecular construct, 
BASP-ORCA3, that features the highest payload of MRI-active chex that has been reported 
to date. In concert with our BASP nanoarchitecture, this high chex density imparts 
outstanding molecular transverse relaxivity while preserving exceptional in vivo stability. 
Due to its very high chex payload, BASP-ORCA3 addresses the low contrast that has, thus 
far, hindered the successful translational development of nitroxide-based MRI CAs. Of 
particular interest is the ability of BASP-ORCA3 to heterogeneously distribute within 
tumors, specifically identifying necrotic regions that may serve as important biomarkers 
(e.g., for radiation resistance). Coupled with the facile ability to prepare BASPs with 
combinations of different therapeutic agents,58–61,77,78 these architectures may provide tools 
for image-guided drug delivery and/or real-time evaluation of therapeutic eﬃcacy. As 
demonstrated in an orthotopic murine model of disseminated human ovarian cancer with 
high clinical relevance, BASP-ORCA3 is able to generate an enhanced T2 signal even within 
poorly vascularized tumor deposits, which enables ready detection of millimetric tumors by 
MRI. Taken together, these data illustrate the translational potential of BASP-ORCA3 for 
applications in early cancer diagnosis and longitudinal therapeutic monitoring. Our work 
further supports the development of nitroxide-based CAs as an alternative to current metal-
based agents for clinical imaging applications.
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METHODS
Synthesis of BASP-ORCAs.
Note: All BASP-ORCA syntheses were performed in a glovebox under N2 atmosphere; 
however, similar results are expected under ambient conditions. All ROMP reactions 
followed the same general procedure, which was modified from reported examples.48,58,59 
Representative procedure for BASP-ORCA synthesis with brush length of 7.07 (m) and 20 
equiv (N) of cross-linker (BASP-ORCA3, x = 3, m = 7.07, N = 20): To a 4 mL vial, a 
suspension of Acetal-XL (12.2 mg, 21.0 μmol, 20.0 equiv) in THF (209.7 μL, 0.1 M Acetal-
XL) was prepared. To a second 4 mL vial containing a stir bar, chex3-MM (34.0 mg, 7.3 
μmol, 7.0 equiv) was added; Cy-MM was then added from a premade 12.5 mg/mL solution 
in THF (24.0 μL, 0.073 μmol, 0.07 equiv). To a third vial, a solution of Grubbs 3rd 
generation bispyridyl catalyst (G3-cat, 0.02 M in THF) was freshly prepared. THF (71.9 μL) 
was then added to the MM vial, followed by the addition of G3-cat solution (52.4 μL, 1.0 
μmol, 1.0 equiv) to give the desired MM/ G3-cat ratio of 7.07:1 (1 mol % of the Cy-MM), 
while achieving a total MM concentration of 0.05 M. The dark blue reaction mixture was 
allowed to stir for 30 min at room temperature before an aliquot (∼5 μL) was taken out and 
quenched with 1 drop of ethyl vinyl ether for GPC analysis. The Acetal-XL suspension was 
then added dropwise (in aliquots of 5 equiv, or ∼50 μL, every 5 min) over the course of 20 
min into the reaction vial, and the dark blue polymerization was allowed to proceed for 6 h 
at room temperature while stirring. To quench the polymerization, a drop of ethyl vinyl ether 
was added. The reaction mixture was transferred to 8 kDa molecular weight cutoff dialysis 
tubing (Spectrum Laboratories) in 5 mL nanopure water, and the solution was dialyzed 
against H2O (500 mL × 3, solvent exchange every 6 h). The dialyzed solution of BASP-
ORCA3 was then concentrated to the desired concentration via centrifugation with a filter 
tube (100 kDa MWCO, Millipore Sigma).
In Vivo MR and NIRF Image Acquisition.
In vivo MR images of the subcutaneous multiple myeloma model were obtained by using a 
7T Bruker BioSpec USR70/30 instrument that is housed in the Lurie Imaging Facility 
Center at the Dana-Farber Cancer Institute (DFCI); in vivo MR images of the disseminated 
xenograft model of advanced-stage ovarian cancer were acquired using a Varian 7T/310/
ASR-whole mouse MRI system housed in the Koch Institute for Integrative Cancer Research 
at MIT. Scans were collected with respiratory gating (PC-SAM version 6.26 by SA 
Instruments Inc.) to avoid noise due to chest movement. The respiratory rate and animal 
temperature were closely monitored during image acquisition. Coronal T2 weighted images 
(T2WIs) were collected by employing the fast spin echo multiple slices pulse sequence with 
TR = 4000 ms; TE(eff) = 48 ms; ETL = 8; FOV = 100 × 50 mm2; 512 × 256 matrix and 2 
averages over 20–30 slices (to capture a maximum number of tumors) that were of 0.5 mm 
thickness and 0.5 mm gap. Axial T2WIs were collected using the fast spin echo multiple 
slices pulse sequence with TR = 4000 ms; TE(eff) = 48 ms; ETL = 8; FOV = 45 × 45 mm2; 
256 × 192 matrix and 2 averages over 20–30 slices (to capture the entire tumor) at 1 mm 
thickness and 1 mm gap. In vivo NIRF-based optical images were obtained by using 
identical IVIS bioluminescence and ﬂuorescence imaging systems (Xenogen) housed in the 
DFCI and MIT facilities. Epiﬂuorescence imaging was acquired through excitation of the 
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Cy5.5 ﬂuorophore (λex/λem = 640/700 nm, exposure time 2–10 s) incorporated within the 
BASP-ORCAs. Imaging of subcutaneous plasmacytomas was performed with animals 
placed on their sides so that their tumors faced the camera; imaging of the disseminated 
ovarian cancer model was performed with animals in the prone position.
In Vivo MR and NIRF-Based Optical Imaging of Tumor-Bearing Mice.
Tumor cells for animal implantation were cultured to a final concentration of 20% (see the 
SI for details). Cells were then harvested, resuspended in sterile pH 7.4 PBS buffer, passed 
through sterile 0.2 μm filters, and injected accordingly. MRI and NIRF-based optical images 
were acquired for each animal before injection. BASP-ORCA solutions (30 mg in PBS, 
injected as 0.25 mL of a 120 mg/mL solution, 0.22 mmol chex/kg for BASP-ORCA1; 0.57 
mmol chex/kg for BASP-ORCA3) were prepared, passed through a sterile 0.2 μm filter, and 
administered to the tumor-bearing mice via iv (subcutaneous model) or ip injection 
(orthotopic model). Tumor imaging by MRI and NIRF-based optical imaging was conducted 
24 h thereafter. Mice were then immediately euthanized in a CO2 chamber; their organs 
were collected, imaged, and stored in dry ice for EPR analysis.
Ex Vivo EPR Spectroscopy.
Harvested organs were shipped on dry ice to the University of Nebraska, where they were 
stored at −80 °C. For EPR sample preparation, each tissue sample, one at a time, was rapidly 
thawed and transferred to a weighed vial; 900 μL of PBS buffer (0.5 mM, pH 7.2) were then 
added. The mixture was put into an ice–water bath and homogenized with a rotor stator 
homogenizer; it was then pipeted into a 4 mm outer diameter EPR sample tube. The samples 
were degassed by sonication as needed (for instance, when gas bubbles were visible). The 
EPR tube was capped, sealed with parafilm, and stored brieﬂy in an acetone/dry ice bath 
before spin concentration measurements. Spin concentrations of nitroxide radicals in tissues 
(μmol chex per g protein; Note: see the SI for details of protein content determination) were 
measured at −30 °C (243.2 K) to increase signal-to-noise of the aqueous samples. 
Measurements of tissue samples were alternated with that of the spin concentration 
reference and g-value reference. For tissue samples with low signal-to-noise, the cavity 
background was recorded with identical parameters, including numbers of scans and 
receiver gain. Typical parameters were as follows: microwave attenuation, 20 dB; 
modulation amplitude, 5 Gauss; spectral width, 300 Gauss; resolution, 512 points; 
conversion, 40.96; time constant, 10.24; and sweep time, 20.97 s. These parameters were 
kept identical for the tissues, references, and cavity backgrounds. The number of scans (8–
256) and receiver gain were adjusted as needed for each sample. The reference for spin 
concentration was 0.50 mM Proxyl in PBS (pH 7.2). This reference was always stored in dry 
ice, except during measurements, and occasionally rechecked for spin concentration decay. 
The g-value reference was 2,2-diphenyl-1-picrylhydrazyl powder.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Chemical structures and scheme for the synthesis of BASP-ORCAs. (A) Structures of 
BASP-ORCA components used in this work and (B) brush-first ring-opening metathesis 
polymerization (ROMP) scheme for the preparation of BASP-ORCA3 pyr = pyridine; Ph = 
phenyl.
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Figure 2. 
In vitro characterization of BASP-ORCA3. (A) Representative transmission electron 
microscopy (TEM) image of BASP-ORCA3 (negatively stained with 2% wt. uranyl acetate). 
Scale bar: 500 nm. (B) Representative dynamic light scattering (DLS) histogram for BASP-
ORCA3. Dh = hydrodynamic diameter. (C) Electron paramagnetic resonance (EPR) spectra 
for BASP-ORCA3 and chex3-MM.
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Figure 3. 
MRI phantoms of BASP-ORCA3. (A) T2-weighted MRI phantoms at the same w/v 
concentrations (from 0 to 3, 6, 8, 12, 15, 18, and 21 mg/mL) of BASP-ORCA1 and BASP-
ORCA3, which vary by chex density. (B) T2-weighted MRI phantoms (top) and 
quantification of in vitro sensitivity (bottom) of BASP-ORCA1 and BASP-ORCA3 at 6 h 
after incubation with MM.1S cells with 21 mg/mL BASP-ORCA solutions.
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Figure 4. 
In vivo imaging of subcutaneous plasmacytomas. (A) In vivo optical imaging (Cy5.5 
fluorescence; λex/λem = 640/700 nm) of MM.1S (multiple myeloma) cells subcutaneously 
implanted in SCID mice (n = 4); the animals were administered either BASP-ORCA1 or 
BASP-ORCA3 by intravenous injection and their tumors were visualized 24 h later by in 
vivo optical imaging. (B) T2-weighted MR images of the same mice pre- and postinjection, 
revealing differences in T2 signal observed from BASP-ORCA1 vs BASP-ORCA3 and in 
both non-necrotic and necrotic tumor regions. (B) Quantitative analysis of contrast 
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enhancements generated by BASP-ORCA1 vs BASP-ORCA3 in the overall tumor versus in 
necrotic regions. Statistical comparisons were acquired with the Mann–Whitney U-test (*not 
significant, **p ≤ 0.05, ***p ≤ 0.01). (D) Colocalization study confirming the specific 
uptake of BASP-ORCA3 (based on its Cy5.5 signal) in necrotic tumor areas as depicted by 
H&E staining.
Nguyen et al. Page 22
ACS Nano. Author manuscript; available in PMC 2019 January 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 5. 
In vivo detection of millimetric tumor deposits in a murine model of disseminated ovarian 
cancer. (A) Growth of luciferase-expressing OVCAR8 (ovarian) tumors monitored by 
bioluminescence imaging (BLI). (B) Tumor accumulation of BASP-ORCA3 qualitatively 
visualized by in vivo optical imaging of its near-infrared fluorescence at 24 h after 
intraperitoneal injection. (C) T2-weighted MR images of the same mice pre- and 
postinjection with BASP-ORCA3, demonstrating millimetric tumors on the serosal surfaces 
of peritoneal organs (yellow arrows). Scale bar: 1 cm. (D) Visual validation of tumor 
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implants (yellow arrows). (E) Quantitative analysis of contrast enhancement generated by 
BASP-ORCA1 vs BASP-ORCA3. Statistical comparisons were acquired with the Mann–
Whitney U-test (*not significant, **p ≤ 0.05, ***p ≤ 0.01).
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Figure 6. 
Quantification of the biodistribution profiles of different BASP-ORCAs via quantification of 
EPR and fluorescence signals in ex vivo organ homogenates from the OVCAR8 (ovarian 
tumor) model. (A) Representative EPR spectra of ex vivo organ homogenates from mice 
administered BASP-ORCA3. (B) Quantification of chex content in each organ by EPR (n = 
4–5), revealing greater amounts of chex across the various organs of mice that were 
administered BASP-ORCA3 vs BASP-ORCA1. (C) Biodistribution profiles as quantified 
from NIRF signals, revealing similar profiles for BASP-ORCA1 and BASP-ORCA3; the 
results support that the higher tumor contrast imparted by BASP-ORCA3 is due to its 
increased chex loading. Statistical comparisons between sample tissues and brain tissue 
were acquired using the Mann–Whitney U-test (*not significant, **p ≤ 0.05, ***p ≤ 0.01).
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